LVW Advisors LLC Takes $242,000 Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

LVW Advisors LLC acquired a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,835 shares of the medical device company’s stock, valued at approximately $242,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TNDM. RiverPark Advisors LLC purchased a new position in shares of Tandem Diabetes Care during the fourth quarter valued at about $27,000. MCF Advisors LLC increased its position in shares of Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares during the period. Signaturefd LLC increased its position in shares of Tandem Diabetes Care by 871.8% during the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after buying an additional 1,517 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Tandem Diabetes Care by 51.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after buying an additional 1,099 shares during the period. Finally, GAMMA Investing LLC purchased a new position in shares of Tandem Diabetes Care during the fourth quarter valued at about $73,000.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Dick Allen sold 5,000 shares of Tandem Diabetes Care stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $51.68, for a total value of $258,400.00. Following the completion of the transaction, the director now directly owns 24,396 shares of the company’s stock, valued at approximately $1,260,785.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Trading Down 0.3 %

Shares of Tandem Diabetes Care stock opened at $40.29 on Monday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.01 and a current ratio of 3.81. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $53.69. The company’s 50 day moving average is $44.52 and its 200 day moving average is $33.97.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.17. The business had revenue of $191.67 million for the quarter, compared to the consensus estimate of $173.06 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. Research analysts predict that Tandem Diabetes Care, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TNDM shares. Citigroup upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and boosted their price target for the company from $40.00 to $57.00 in a research report on Wednesday, May 22nd. Stifel Nicolaus upped their price objective on shares of Tandem Diabetes Care from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Lake Street Capital upped their price objective on shares of Tandem Diabetes Care from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. Finally, Piper Sandler restated an “overweight” rating and issued a $50.00 price objective (up previously from $35.00) on shares of Tandem Diabetes Care in a report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.25.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.